| Old Articles: <Older 23391-23400 Newer> |
|---|
 |
The Motley Fool
May 22, 2007
Anders Bylund |
A Tale of 2 Idols, 2 Sodas The "American Idol" finalists look a lot like soft drink companies, don't you think? Investors, here is the parallel to Coca-Cola and Pepsi.   |
The Motley Fool
May 22, 2007
Rick Aristotle Munarriz |
More High Scores at NetEase Investors, the Chinese firm and its increasingly popular games beat Wall Street again. |
The Motley Fool
May 22, 2007
Mike Cianciolo |
Still Dreary at Pacific Sunwear The surf and skate retailer posts a loss in the quarter but indicates there may finally be a clearing ahead. Investors, take note. |
The Motley Fool
May 22, 2007
Tom Taulli |
Breaking the NetBank While it's possible for the online bank to stabilize, there's not much left to provide for a sustainable business. That won't stop daredevil traders from playing the stock, but this is definitely no place for wise investors. |
The Motley Fool
May 22, 2007
Mike Havrilla |
Savient Seems Set for a Success With generic competition against one drug, the company is ready to produce another. Biotech investors are encouraged to take a look here. |
The Motley Fool
May 22, 2007
Mike Cianciolo |
Gloomy Days Remain at PacSun: Fool by Numbers The specialty apparel retailer released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
May 22, 2007
Brian Lawler |
Elan Plunges Ahead Shares of the drugmaker Elan have climbed more than 20% in the past two days after the company announced that it and partner Wyeth were moving their lead Alzheimer's disease treatment into phase 3 testing. |
The Motley Fool
May 22, 2007
Mac Greer |
Fool Video Take: Microsoft Deals With Google Stock analysts discuss whether Microsoft's latest buy was a good deal or an act of desperation. |
The Motley Fool
May 22, 2007
Mike Havrilla |
Avandia Safety Concerns Weigh Down Glaxo Shares of GlaxoSmithKline dropped nearly 8%, after a study raised safety concerns about the company's widely used diabetes drug, Avandia. |
The Motley Fool
May 22, 2007
Alyce Lomax |
Sony Plays Around With PS3 The electronics giant's most recent quarter may have given investors hope that its turnaround is nigh, but the drama surrounding its PlayStation 3 continues. |
| <Older 23391-23400 Newer> Return to current articles. |
